Evidence map›Paper›PMID 36777049›Full record

ArticleChem2023

Xuedan Wu, Wei Chen, Natalie Holmberg-Douglas, Gerald Thomas Bida, Xianshuang Tu, Xinrui Ma, Zhanhong Wu, David A Nicewicz, Zibo Li

Abstract read
In one paragraph

Article in Chem, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Recent advances in [Nuclear medicine and biology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. One-Step Synthesis of [ACS central science · 2024
    Article
  8. Article
  9. Article
  10. Photo- and Cu-MediatedOrganic letters · 2024
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xuedan WuBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC 27514, USA.
Wei ChenBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC 27514, USA.
Natalie Holmberg-DouglasDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599-3290, United States.
Gerald Thomas BidaBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC 27514, USA.
Xianshuang TuBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC 27514, USA.
Xinrui MaBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC 27514, USA.
Zhanhong WuBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC 27514, USA.
David A NicewiczDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599-3290, United States.
Zibo LiBiomedical Research Imaging Center, Department of Radiology, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC 27514, USA.

Funding

Novel Catalytic Methods for Efficient Radiolabeling of Un-activated Arene Compounds SupplementR01EB029451 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO, NICEWICZ, DAVID A · 2020 to 2023
$2.2M
The development of novel PET/NIRF agents for hyperparathyroidism managementR01DK128447 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM, LAWRENCE THOMAS, WU, ZHANHONG · 2021 to 2024
$2.0M
Development of IDO PET agents for immunotherapyR01CA233904 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO, MOSCHOS, STERGIOS · 2019 to 2023
$2.0M
Small Animal PET/CT for Preclinical Imaging ResearchS10OD023611 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LI, ZIBO · 2017 to 2017
$835k
NCI NIH HHS R01 CA233904NIBIB NIH HHS R01 EB029451NIDDK NIH HHS R01 DK128447NIH HHS S10 OD023611
6 · The paper itself

Abstract

As a non-invasive imaging technology, positron emission tomography (PET) plays a crucial role in personalized medicine, including early diagnosis, patient screening, and treatment monitoring. The advancement of PET research depends on the discovery of new PET agents, which requires the development of simple and efficient radiolabeling methods in many cases. As bioisosteres for halogen and carbonyl moieties, nitriles are important functional groups in pharmaceutical and agrochemical compounds. Here, we disclose a mild organophotoredox-catalyzed method for efficient cyanation of a broad spectrum of electron-rich arenes, including abundant and readily available veratroles and pyrogallol trimethyl ethers. Notably, the transformations not only are compatible with various affordable

Indexed as

Carbon-11carbon-13cyanationdimethoxy arenenitrilePETphotoredox catalysisradiolabelingtrimethoxy arene

Identifiers

PMID36777049
PMCPMC9913897

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.